Drug Trial Radar · NCT06903338
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
124
Actual
Start
Mar 12, 2025
Primary completion
Sep 30, 2026
Study completion May 2031
Sponsor
- Lead sponsor
- Vir Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
Conditions
- Viral Hepatitis
Interventions
TobevibartDrug
Tobevibart administered by subcutaneous injection
ElebsiranDrug
Elebsiran administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- HDV RNA < Lower Limit of Quantification (LLOQ), Target Not Detected (TND) and alanine aminotransferase (ALT) normalization (ALT </= Upper Limit of Normal [ULN]) at Week 48 for Arm 1 vs at Week 12 for Arm 2Time frame: Up to 48 weeks
- Incidence of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 12Time frame: Up to 12 weeks
Locations
39 sites in 10 countries. Site status is shown where the registry gives one.
Investigative Site
Chandler, Arizona
Investigative Site
Los Angeles, California
Investigative Site
Redwood City, California
Investigative Site
San Francisco, California
Investigative Site
DeLand, Florida
Investigative Site
Chicago, Illinois
Investigative Site
Baltimore, Maryland
Investigative Site
Hillsborough, New Jersey
Investigative Site
New York, New York
Investigative Site
New York, New York
Investigative Site
New York, New York
Investigative Site
Murray, Utah
Investigative Site
Seattle, Washington
Investigative Site
Montreal, Canada
Investigative Site
Ottawa, Canada
Investigative Site
Québec, Canada
Investigative Site
Vancouver, Canada
Investigative Site
Calgary, Alberta, Canada
Investigative Site
Montreal, Quebec, Canada
Investigative Site
Tbilisi, Georgia
Investigative Site
Tbilisi, Georgia
Investigative Site
Tbilisi, Georgia
Investigative Site
Frankfurt, Germany
Investigative Site
Hanover, Germany
Investigative Site
Heidelberg, Germany
Investigative Site
Chisinau, Moldova
Investigative Site
Auckland, New Zealand
Investigative Site
Karachi, Pakistan
Investigative Site
Karachi, Pakistan
Investigative Site
Lahore, Pakistan
Investigative Site
Rawalpindi, Pakistan
Investigative Site
Bucharest, Romania
Investigative Site
Bucharest, Romania
Investigative Site
Bucharest, Romania
Investigative Site
Kyiv, Ukraine
Investigative Site
London, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
Manchester, United Kingdom
Investigative Site
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.